An experimental drug is showing promise in slowing the decline in thinking and memory that comes with Alzheimer’s disease, especially in people with milder forms of the illness.
Drug maker Eli Lilly & Co. announced Monday that solanezumab did not slow mental decline in each of two phase 3 clinical trials, but when the data from both studies was combined a statistically significant and positive effect was seen. This benefit seemed to be concentrated in patients with mild cases of Alzheimer’s, the company noted.
In a news release, Lilly said that combining the results of the two trials showed a 34 percent slowing of mental decline for people with mild Alzheimer’s who took solanezumab, compared to those taking a placebo.
The trial data was released Monday at an American Neurological Association conference in Boston.
“We recognize that the solanezumab studies did not meet their primary endpoints, but we are encouraged by the pooled data that appear to show a slowing of cognitive [thinking/memory] decline,” Lilly Chairman, CEO and President John Lechleiter said in a company news release.
Read the full article from Healthy Day at http://consumer.healthday.com/Article.asp?AID=669437.
Comments are closed.
"We want to thank you for the loving special care you took of our mother, Diane. It was truly mom's home and you all became part of our family. Everything was home for her....from the beautiful rooms, large sunny windows all around, good food made with love, fun and personal activities from people who really loved our mom. We would highly recommend your facility to anyone. The staff from the director, to the doctor, to the nurse, to the caregivers and the maintenance man were all extremely helpful, caring, loving and professional. There are not enough words to say how much we appreciate all of you. Your exceptional care, kindness, and love were beyond anything we could have imagined. You were part of our family, and we will miss you." - Gail Sommers and Deborah Guse